Our work has been featured in the Budget Presentation by the University of Pittsburgh Chancellor to the General Assembly of the Commonwealth of Pennsylvania (2022-2023):
"Industry collaborations also are a major part of Pitt’s growing portfolio of ophthalmology research. Under the leadership of Jose- Alain Sahel, Distinguished Professor and chair of Pitt’s Department of Ophthalmology, Pitt has launched new translational research programs aimed at developing curative treatments for debilitating diseases that lead to vision loss. One such program is a research collaboration with Astellas Pharma Inc. focused on the discovery and optimization of gene therapies for the treatment of dry age-related macular degeneration (dry AMD). In this collaboration, Debasish Sinha, the Jennifer Salvitti Davis, MD, Chair in Ophthalmology Research and professor of ophthalmology, cell biology and developmental biology at the Pitt School of Medicine, a world- renowned authority in the research field of back- of-the-eye diseases, and Astellas, which has capabilities in drug discovery, are working jointly to evaluate and optimize the drug candidates, with an aim of providing new treatment options that help patients suffering from dry AMD to recover and maintain their vision"
